公开(公告)号：US20230293440A1

公开(公告)日：2023-09-21

申请号：US18180801

申请日：2023-03-08

Applicant: ACCESS TO ADVANCED HEALTH INSTITUTE

Inventor： Christopher B. FOX ,  Thomas VEDVICK ,  Lucien BARNES, V ,  Ryan M. KRAMER ,  Steven G. REED

IPC: A61K9/19 ,  A61K39/00 ,  A61K39/04 ,  A61K39/39 ,  A61K47/22 ,  A61K47/26 ,  A61K47/10

CPC classification number: A61K9/19 ,  A61K39/00 ,  A61K39/04 ,  A61K39/39 ,  A61K47/22 ,  A61K47/26 ,  A61K47/10 ,  A61K2039/55572 ,  A61K2039/552 ,  A61K2039/55511

Abstract: The invention provides for thermostable lyophilized formulations, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response, and methods of use thereof. The lyophilized formulations generally comprise an antigen and/or an adjuvant, a metabolizable oil, and a cake-forming excipient.

公开(公告)号：US20230287038A1

公开(公告)日：2023-09-14

申请号：US18020253

申请日：2021-06-04

Applicant: ACCESS TO ADVANCED HEALTH INSTITUTE

Inventor： Yizhi QI ,  Christopher Bradford FOX

IPC: C07J63/00 ,  A61K39/39 ,  G01N30/86 ,  G01N30/72 ,  B01D15/30 ,  B01D15/32

CPC classification number: C07J63/008 ,  A61K39/39 ,  G01N30/8631 ,  G01N30/72 ,  B01D15/305 ,  B01D15/325 ,  A61K2039/55577

Abstract: Substantially pure saponin extracts and orthogonal chromatographic methods for purification of saponin extracts are disclosed. The purified saponin extracts may include QS-21 and can have a purity of greater than 97%. The orthogonal chromatographic method uses reversed-phase (RP) chromatography followed by hydrophilic interaction liquid chromatography (HILIC) to generate substantially pure saponin extracts.

公开(公告)号：US20230116042A1

公开(公告)日：2023-04-13

申请号：US17960110

申请日：2022-10-04

Applicant: ACCESS TO ADVANCED HEALTH INSTITUTE

Inventor： Christopher FOX ,  Steven G. REED ,  Susan BALDWIN ,  Thomas VEDVICK

IPC: A61K9/113 ,  A61K39/00 ,  A61K9/107 ,  A61K39/39 ,  A61K39/12 ,  A61K47/06 ,  A61K47/24 ,  A61K39/015 ,  A61K47/26

Abstract: Formulations and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed. The formulations generally comprise a TLR4 agonist and a metabolizable oil at a concentration of about 0.01%-1% v/v, wherein the hydrophobic:lipophilic balance (HLB) of the emusion is greater than about 9.

公开(公告)号：US20220257754A1

公开(公告)日：2022-08-18

申请号：US17731718

申请日：2022-04-28

Applicant: ACCESS TO ADVANCED HEALTH INSTITUTE

Inventor： Christopher B. FOX

IPC: A61K39/39 ,  A61K39/04 ,  A61K39/12 ,  C07K14/705 ,  A61K35/76 ,  A61K45/06 ,  A61P31/12 ,  A61P33/04 ,  A61P31/06 ,  A61P35/00

Abstract: Stable aqueous formulations of adjuvant comprising a TLR7/8 agonist or a TLR4 agonist with a helper lipid that are adsorbed to alum are provided. Compositions and methods of using the formulations for stimulating an immune response are also provided.

公开(公告)号：US11376325B2

公开(公告)日：2022-07-05

申请号：US16899729

申请日：2020-06-12

Applicant: ACCESS TO ADVANCED HEALTH INSTITUTE

Inventor： Steven G. Reed ,  Darrick Carter

IPC: A61K39/395 ,  A61K39/39 ,  A61K39/008 ,  A61K45/06 ,  A61K39/04 ,  A61K39/145 ,  A61K39/00 ,  C12N7/00

Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.

公开(公告)号：US12201722B2

公开(公告)日：2025-01-21

申请号：US17470874

申请日：2021-09-09

Applicant: ACCESS TO ADVANCED HEALTH INSTITUTE

Inventor： Christopher B. Fox ,  Amit Praful Khandhar ,  Neal Van Hoeven ,  Jesse H. Erasmus ,  Susan S. Lin

IPC: A61K9/107 ,  A61K9/127 ,  A61K31/713 ,  A61K39/39 ,  A61K47/10 ,  A61K47/26 ,  C07K16/10 ,  A61K45/06

Abstract: Provided herein are nanostructured lipid carrier compositions, and methods of making and using thereof. The compositions comprise a nanostructured lipid carrier (NLC), where the NLC comprises an oil core comprising a mixture of a liquid phase lipid and a solid phase lipid, a cationic lipid, a sorbitan ester, and a hydrophilic surfactant, and optionally a bioactive agent. The bioactive agent can be associated with the NLC. The compositions are capable of delivery of a biomolecule to a cell for the generation of an immune response, for example, for vaccine, therapeutic, or diagnostic uses. Compositions and methods related to making the compositions and using the compositions for stimulating an immune response are also provided.

公开(公告)号：US20240050561A1

公开(公告)日：2024-02-15

申请号：US18269284

申请日：2021-10-16

Applicant: ACCESS TO ADVANCED HEALTH INSTITUTE

Inventor： Christopher Bradford FOX

IPC: A61K39/39 ,  A61K39/145 ,  A61K47/22 ,  A61K9/107 ,  A61P37/04

CPC classification number: A61K39/39 ,  A61K39/145 ,  A61K47/22 ,  A61K9/1075 ,  A61P37/04 ,  A61K2039/55566

Abstract: This disclosure describes the use of solanesol as an adjuvant in vaccine compositions, as well as related prophylactic and therapeutic methods. Solanesol may be used to replace squalene in vaccine compositions with similar or superior immunostimulatory effects. Solanesol, which is solid at room temperature, may be formulated for use in vaccine compositions by heating above its melting temperature in an aqueous solution to form a dispersion.

公开(公告)号：US20230381292A1

公开(公告)日：2023-11-30

申请号：US18190934

申请日：2023-03-27

Applicant: ACCESS TO ADVANCED HEALTH INSTITUTE

Inventor： Steven G. REED ,  Malcolm S. DUTHIE

IPC: A61K39/04 ,  A61K39/39

CPC classification number: A61K39/04 ,  A61K39/39 ,  A61K2039/55561

Abstract: Compositions and methods for preventing, treating and detecting leprosy are disclosed. The compositions generally comprise polypeptides comprising one or more Mycobacterium leprae antigens as well as polynucleotides encoding such polypeptides.

公开(公告)号：US20230338501A1

公开(公告)日：2023-10-26

申请号：US18024703

申请日：2021-07-04

Applicant: ACCESS TO ADVANCED HEALTH INSTITUTE

Inventor： Neal VAN HOEVEN ,  Emily VOIGT

IPC: A61K39/12 ,  C12N7/00 ,  A61P31/14 ,  A61K9/107

CPC classification number: A61K39/12 ,  C12N7/00 ,  A61P31/14 ,  A61K9/1075 ,  A61K2039/53

Abstract: This disclosure provides ribonucleic acid (RNA) polynucleotides encoding replication-competent viral genomes that, when introduced to a subject, induce an active viral replication. The RNA may be provided naked or with an artificial RNA delivery system. The viral genome may be a full-length genome of an attenuated viral strain. For example, the RNA may encode an attenuated Chikungunya or yellow fever virus. The artificial RNA delivery system may be a lipid particle such as a lipid nanoparticle (LNP), a nanostructure lipid carrier (NLC), or a cationic nanoemulsion (CNE). This disclosure also provides methods of inducing an immune response, including protective immunity, by administering to a subject an RNA polynucleotide that encodes a replication-competent viral genome in an amount sufficient to cause viral replication in the subject. The immune response may include inducing the production of neutralizing antibodies at a level comparable to inoculation with a live-attenuated virus.

公开(公告)号：US20230310569A1

公开(公告)日：2023-10-05

申请号：US18024727

申请日：2021-07-04

Applicant: ACCESS TO ADVANCED HEALTH INSTITUTE

Inventor： Emily VOIGT

IPC: A61K39/12 ,  A61K39/39

CPC classification number: A61K39/12 ,  A61K39/39 ,  A61K2039/53

Abstract: The present application discloses a genetically-adjuvanted RNA vaccine including one or more genes encoding immune stimulatory adjuvants in the genetic material of the vaccine backbone. The vaccine may be applied to enhance the magnitude, diversity, and durability of RNA vaccine-stimulated immunity in a subject.